CDC20/HSP90-IN-1

CDC20/HSP90-IN-1 (Compound 2b) is a Cdc20/Hsp90 inhibitor with a Kd of 16.2 μM for Cdc20 and a Kd of 0.241 μM for Hsp90α. CDC20/HSP90-IN-1 exerts potent antitumor activity through reducing p53-mediated Cdc20, upregulating Bim, downregulating Cyclin B1 expression, and disturbing B-Raf and AKT pathways via destroying Hsp90 chaperone function. CDC20/HSP90-IN-1 overcomes Vemurafenib (HY-12057) -induced resistant melanoma[1].

Product Specifications

Target

Akt; APC; CDK; HSP; Raf

Related Pathways

Cell Cycle/DNA Damage; MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Field of Research

Cancer

Smiles

O=C(NC(C(Cl)(Cl)Cl)NC1=NC=CC=N1)OCCOCCOCC2=CN(N=N2)CCC#CC3=CN(C4=NC(N)=NC(Cl)=C43)CC5=C(C(OC)=C(C=N5)C)C

Molecular Formula

C33H36Cl4N12O5

Molecular Weight

822.53

References & Citations

[1]Chen Q, et al. Discovery of Cdc20/Hsp90 Dual-Target Inhibitors with Potent Antitumor Activity for Therapy of Acquired Resistant Melanoma. J Med Chem. 2025 Nov 13;68 (21) :22428-22454.